Impax Asset Management Group plc Lowers Position in Repligen Co. (NASDAQ:RGEN)

Impax Asset Management Group plc lessened its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 6.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,058,169 shares of the biotechnology company's stock after selling 68,709 shares during the quarter. Impax Asset Management Group plc owned about 1.89% of Repligen worth $156,441,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Repligen by 30.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company's stock valued at $5,312,000 after buying an additional 6,705 shares in the last quarter. Swedbank AB acquired a new stake in Repligen in the first quarter valued at about $5,518,000. Banque Pictet & Cie SA raised its position in Repligen by 74.6% in the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock valued at $4,351,000 after purchasing an additional 14,746 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company's stock worth $937,994,000 after purchasing an additional 21,719 shares during the last quarter. Finally, Diversified Trust Co increased its stake in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after buying an additional 106 shares during the period. Institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on RGEN. Stephens reissued an "overweight" rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price on the stock. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Trading Up 4.6 %

Shares of Repligen stock traded up $6.42 on Tuesday, reaching $145.95. 373,671 shares of the company's stock were exchanged, compared to its average volume of 657,236. The company has a market capitalization of $8.17 billion, a P/E ratio of -3,647.84, a price-to-earnings-growth ratio of 3.98 and a beta of 0.96. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm's 50-day moving average is $141.90 and its two-hundred day moving average is $145.52.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.